Arnott ID - Search Results

1

Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease.

Russell RK, Ip B, Aldhous MC, MacDougall M, Drummond HE, Arnott ID, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Wilson DC, Satsangi J. Russell RK, et al. Among authors: arnott id. J Pediatr Gastroenterol Nutr. 2009 Feb;48(2):161-7. doi: 10.1097/MPG.0b013e318183e112. J Pediatr Gastroenterol Nutr. 2009. PMID: 19179877

2

Validation of the ACE [Albumin, CRP, and Endoscopy] Index in Acute Colitis: Analysis of the CONSTRUCT dataset.

Grant RK, Jones GR, Plevris N, Lynch RW, Brindle WM, Hutchings HA, Williams JG, Alrubaiy L, Watkins A, Lees CW, Arnott IDR. Grant RK, et al. Among authors: arnott idr. J Crohns Colitis. 2024 Feb 26;18(2):286-290. doi: 10.1093/ecco-jcc/jjad148. J Crohns Colitis. 2024. PMID: 37615649 Clinical Trial.

3

Gut mucosal secretion of interleukin 1beta and interleukin-8 predicts relapse in clinically inactive Crohn's disease.

Arnott ID, Drummond HE, Ghosh S. Arnott ID, et al. Dig Dis Sci. 2001 Feb;46(2):402-9. doi: 10.1023/a:1005617302718. Dig Dis Sci. 2001. PMID: 11281191

4

Gut luminal neutrophil migration is influenced by the anatomical site of Crohn's disease.

Arnott ID, Drummond HE, Ghosh S. Arnott ID, et al. Eur J Gastroenterol Hepatol. 2001 Mar;13(3):239-43. doi: 10.1097/00042737-200103000-00004. Eur J Gastroenterol Hepatol. 2001. PMID: 11293442

5

Frequency of continuing mucosal inflammation in clinically inactive Crohn's disease.

Arnott ID, Drummond HE, Ghosh S. Arnott ID, et al. Scott Med J. 2001 Oct;46(5):136-9. doi: 10.1177/003693300104600504. Scott Med J. 2001. PMID: 11771492

6

Whole gut lavage fluid interleukin-1beta and interleukin-8 in smokers and non-smokers with Crohn's disease in clinical remission.

Arnott ID, Williams N, Drummond HE, Ghosh S. Arnott ID, et al. Dig Liver Dis. 2002 Jun;34(6):424-9. doi: 10.1016/s1590-8658(02)80040-8. Dig Liver Dis. 2002. PMID: 12132790

7

Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety.

Arnott ID, Watts D, Satsangi J. Arnott ID, et al. Pharmacol Res. 2003 Jan;47(1):1-10. doi: 10.1016/s1043-6618(02)00264-5. Pharmacol Res. 2003. PMID: 12526855 Review.

8

Crohn's disease or Crohn's diseases?

Arnott ID, Satsangi J. Arnott ID, et al. Gut. 2003 Apr;52(4):460-1. doi: 10.1136/gut.52.4.460. Gut. 2003. PMID: 12631650 Free PMC article. No abstract available.

9

An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease.

Arnott ID, McNeill G, Satsangi J. Arnott ID, et al. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1451-7. doi: 10.1046/j.1365-2036.2003.01574.x. Aliment Pharmacol Ther. 2003. PMID: 12823146 Free article.

10

Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations.

Walker LJ, Aldhous MC, Drummond HE, Smith BR, Nimmo ER, Arnott ID, Satsangi J. Walker LJ, et al. Among authors: arnott id. Clin Exp Immunol. 2004 Mar;135(3):490-6. doi: 10.1111/j.1365-2249.2003.02392.x. Clin Exp Immunol. 2004. PMID: 15008984 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132 results

Search Page

Filters